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Abstract
Background: Tetralogy of  Fallot (TOF) is the most common cyanotic congenital heart defect (CHD) with an incidence of  
1/3600 live births. This disorder was associated with mutations in the transcription factors involved in cardiogenesis, like Nk2 
homeobox5 (NKX2-5), GATA binding protein4 (GATA4) and T-BOX1 (TBX1). GATA4 contributes particularly to heart loop-
ing and differentiation of  the second heart field.
Objectives: The aim of  this study was to screen a Moroccan cohort with tetralogy of  Fallot for GATA4 mutations, and to assess 
environmental risk factors that could be involved in the occurrence of  this disorder.
Methods: Thirty-one non-syndromic TOF patients, enrolled between 5th April 2014 and 18th June 2015, were screened for 
GATA4 mutations using direct sequencing of  GATA4 coding exons. Statistical assessment of  different risk factors, which is a 
retrospective study, was carried out using Chi-square and Fisher’s exact tests. 
Results: We identified seven exonic variants in nine patients (two missense and five synonymous variants); in addition of  eight 
intronic variants. Assessment of  environmental risk factors shows significant association of  maternal passive smoking with TOF 
in the Moroccan population.
Conclusion: The present study allowed, for the first time, the molecular and environmental characterisation of  Moroccan TOF 
population. Our findings emphasise particularly the strong association of  passive smoking with the emergence of  tetralogy of  
Fallot.
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Introduction 
Tetralogy of  Fallot (TOF) is the most common type of  
cyanotic congenital heart defect, affecting approximately 
1/3,600 live births1. This cyanotic defect is characterised 
by the combination of  four cardiac anomalies: ventricular 
septal defect; over-riding aorta; right ventricular outflow 
obstruction and right ventricular hypertrophy. Approx-
imately 20-25% of  TOF occurs within the context of  
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syndromes, particularly with 22q11 microdeletion syn-
drome2. 
TOF is one of  the multifactorial disorders that results 
from interaction of  environmental and genetic factors. 
Environmental factors include maternal toxic exposure 
(smoking, alcohol, organic solvents), maternal illness with 
use of  medication, and consanguinity among others1. 
Whereas, genetic factors consists mainly of  molecular al-
teration of  genes involved in cardiogenesis1.
Several genes were proved to be involved in non-syn-
dromic Tetralogy of  Fallot. The most evident are those 
encoding the cardiac transcription factors, such as GATA 
binding protein 4 (GATA4), which is involved in the sec-
ond heart field differentiation and heart looping during 
the cardiogenesis process3,4. 
GATA4 (GATA-binding protein 4), member of  GATA 
transcription factor family, is a zinc-finger protein that 
specifically bind to (T/A)GATA(A/G) motif  in target 
genes. GATA4 interact with Nk2 homeobox 5 (NKX2-5) 
and T-BOX 5 (TBX5) within a complex regulatory net-
work to regulate the down-stream genes involved in heart 
development process3. 
In Lebanese and Chinese populations, GATA4 mutations 
are estimated to be present in 3 - 8% of  patients with Te-
tralogy of  Fallot5,6.  Whereas, in other TOF populations, 
such as the American and Japanese, the GATA4 mutation 
rate seems to be very low, about 0.5 - 0.8%4,7. 
Therefore, the aim of  this study was to identify, for the 
first time, the spectrum of  GATA4 variants and to as-
sess the environmental risk factors that may contribute 
potentially in the emergence of  tetralogy of  Fallot in a 
non-syndromic Moroccan population.  
Methods
Study subjects
In this retrospective study, thirty-six patients, with ages 
ranging from 2 months to 15 year-old, were enrolled be-
tween 5th April 2014 and 18th June 2015 from the car-
dio-pediatics department. Each patient was evaluated via 
electrocardiography (ECG) and colour Doppler echocar-
diography, and confirmed to have tetralogy of  Fallot. All 
patients were clinically evaluated for putative syndromic 
dysmorphology, and tested for chromosomal rearrange-
ments (using karyotype) and 22q11 microdeletion by the 
Medical Genetics Department.  Five subjects with con-
firmed or suggestive syndromic traits were excluded from 
the study. The included patients were interviewed to as-
sess the personal and familial disease history.
Molecular screening
After obtaining informed consent as well as the Approval 
of  the local ethic committee, the peripheral blood was 
collected from the 31 non-syndromic tetralogy of  Fallot 
patients, then the DNA specimens were extracted from 
blood leukocytes. For each sample, we performed Poly-
merase chain reaction (PCR) to amplify GATA4 coding 
exons and their intron boundaries. Primers used were de-
rived from previous study8.
PCR mix was prepared in a 25 µL volume comprising 
10× PCR buffer (Invitrogen, California, CA, USA), 25 
mM MgCl2, 10 mM dNTP, 1 U of  Taq (Invitrogen, Cali-
fornia, CA, USA), 10 pmol of  each primer and 40 ng of  
genomic DNA. The PCR cycling conditions performed 
in the Veriti 96-well Thermal Cycler 9902 (Applied Bio-
systems, Massachusetts, MA, USA) were 94 °C for 5 min; 
35 cycles of: 94 °C for 45 s, 59 - 62 °C (according to 
the specific annealing temperature relative to each pair of  
primers) for 40 s, and 72 °C for 45 s; and 72°C for 7 min.
The purified PCR products underwent direct sequencing 
using the BigDye Terminator V1.1 Cycle Sequencing Kit 
(ABI Prism, Applied Biosystems, Massachusetts, MA, 
USA) and the Applied Biosystems 3500Dx Genetic Anal-
yser, then chromatograms were analysed by Sequencing 
Analysis SeqA v.5.4 (Applied Biosystems, Massachusetts, 
MA, USA). The sequences thus obtained were analysed 
with the Bioinformatics analysis tool “Nucleotide Blast 
alignment program”, (http://blast.ncbi.nlm.nih.gov) 
(NCBI, Maryland, MD, USA). 
Statistical analysis
To assess the significance of  differences between the var-
ious rates through the study, we used chi-square tests for 
large cohort (>5) and Fisher’s exact test for smaller co-
hort sizes. The statistical analysis was performed using 
the R software package version 3.2.
Results
Environmental features
A total of  31 patients with non-syndromic tetralogy of  
Fallot were recruited for GATA4 mutation screening. The 
cohort included 14 females and 17 males. The average age 
was 1 year-old at diagnosis, and 6 year-old at enrolment. 
All enrolled subjects were Moroccan with 80% of  them 
from the Central North region of  Morocco. 
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Patients born to consanguineous marriages represented 
20.8% of  the studied population. Averages of  maternal 
and paternal ages were 28 and 38 years respectively. More 
than a third of  patients (38%) had at least one incident 
of  neonatal sibling death or spontaneous abortion in ma-
ternal obstetric history. Interestingly, we noticed a high 
frequency (47.6%) of  second-hand smoking during the 
concerned pregnancies. 
Molecular screening
In this study, we investigated DNA samples of  31 
non-syndromic TOF patients for GATA4 variants. Mu-
tation screening revealed seven variants: two missense 
variants, rs114868912 and rs3729856; four synonymous 
variants that were previously reported, rs192122549, 
rs55788387, rs3729855 and rs112435835; in addition to a 
novel synonymous variant. We also identified eight poly-
morphisms spread over the intronic regions. Figure 1 and 
tables 1 and 2 show further details.
 
 
Figure 1: (a) Organisation of GATA4 domains with position of the identified exonic  
variants. (b-h) Sequencing chromatograms showing the exonic variants detected  
in GATA4. NLS: nuclear localization signal, TAD: Transcriptional activation domain,  
ZF: zinc finger. 
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Table 1: GATA4 exonic variants identified among 31 patients with non-syndromic TOF. 








Mutation type Patients 
rs192122549 8:11606438 c.627C>T Asp209Asp 2 Synonymous P2 
Novel 8:11606498 c.687G>A Arg229Arg 2 Synonymous P7 
rs55788387 8:11606510 c.699G>A Thr233Thr 2 Synonymous P21 
rs3729855 8:11614502 c.1056C>T Asn352Asn 5 Synonymous P6 
rs112435835 8:11614559 c.1113A>G Ser371Ser 5 Synonymous P6 
rs3729856 8:11614575 c.1129A>G Ser377Gly 5 Missense P2,P4, P8, 
P10, P11 
rs114868912 8:11614584 c.1138G>A Val380Met 5 Missense P4 
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Exon/ intron variant type Patients Frequency (%) 
Novel 8:11606365 c.617-63C>A Intron 1 Non-coding P7 3.2 





rs3735819 8:11606312 c.617-116T>C Intron 1 Non-coding P5, P7, 6.5 
rs200555437 8:11606610 c.783+16G>A Intron 2 Non-coding P31   


















Intron 4 Non-coding P2 3.2 
 
Discussion 
GATA4 is a zinc-finger transcription factor that plays a 
major role during different stages of  embryonic heart de-
velopment. Association of  GATA4 with congenital heart 
disease was emphasised, for the first time, in 1999 by Pe-
hlivan et al. who were studying a cohort with 8p23 mi-
crodeletion, a region that carries GATA49. Then, the sub-
sequent studies confirmed the involvement of  GATA4 
mutations in different CHD types, with mutation rates 
varying across ethnic populations. Thus, the aim of  the 
present study was to identify the spectrum and the rate 
of  GATA4 mutations in a Moroccan population with 
non-syndromic TOF, and also to discuss the factors that 
may increase the risk of  having tetralogy of  Fallot. 
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Assessment of  environmental risk factors
Sex-ratio in the studied TOF cohort was 1.2, reflecting 
a slightly higher proportion of  males. An identical ratio 
has been reported by Sarikouch et al., 201110, Rauch et al., 
201011 and Lindinger et al., 201012. In our cohort, con-
sanguinity rate accounts for 20.8%. This rate does not 
seem to be significantly different from the general con-
sanguinity rate in Moroccan population, that is reported 
to be around 15.25% (p = 0.4)13. Indeed, the association 
between consanguinity and CHDs differs from a subset 
to another, and also across populations.  Thus, our data is 
consistent with a previous study conducted in Saudi pop-
ulation14, in which there was no significant relationship 
between consanguinity and tetralogy of  Fallot sub-group, 
but different from Lebanese15,16 and Indian17 studies that 
reported a significant association. The non-association 
observed in our cohort suggests probably a different 
mode of  inheritance or sporadic events. 
According to previous studies, advanced parental age is 
said to have no particular association with tetralogy of  
Fallot alongside several CHD subsets18,19. We noticed in 
our cohort high rates of  previous miscarriage in maternal 
obstetric histories and sibling’s neonatal sudden death, 
respectively 28.5% and 9.5%. According to the National 
Survey on Population and Family Health, 2011 (ENPSF 
– 2011) conducted by Moroccan ministry of  health in the 
general population, the rate of  perinatal death is limited 
to 2.8%20, which does not constitute a significant differ-
ence to our data (p = 0.12). Our conclusion confirms the 
studies conducted by Hassan et al.21 and Roodpeyma et 
al.22 respectively in a Pakistani and Iranian populations 
that attempted to assess the relationship between previ-
ous maternal abortion or perinatal sudden death among 
sibling and CHDs, but did not find a significant associa-
tion. In contrast, other studies prove that previous abor-
tions may be associated with the likelihood of  having a 
child with CHD23,24. 
Considering the sociocultural and religious characteristics 
of  the Moroccans, maternal smoking or alcohol exposure 
is very unusual, unlike the paternal’s.  Thus, to assess the 
relationship between this well-known cardiovascular risk 
factor and TOF, we rather checked the maternal passive 
smoking during the concerned pregnancy.  Interestingly, 
we noticed in our cohort that 47.6% of  mothers were 
exposed to passive smoking during the concerned preg-
nancy. This rate is significantly higher compared to that 
described in a Moroccan ministry of  health report based 
on the Global Youth Tobacco Survey (GITS), in which 
the passive smoking rate in families of  Moroccan general 
population was about 19.7% (p = 0.003)25. These find-
ings lead us to conclude that exposure to passive smoking 
during pregnancy could be a potential risk factor for te-
tralogy of  Fallot. This conclusion is consistent with the 
Heart Disease and Stroke Statistics -2016 Update26.  
GATA4 variants
GATA4 mutation screening of  31 non-syndromic TOF 
patients allowed us to identify two heterozygous missense 
variants. The first variant c.1138G>A (rs114868912), 
found in P4, leads to the Valine-to-Methionine amino 
acid change at the position 380. While the second mis-
sense variant c.1129A>G (rs3729856) found in five pa-
tients (16%) results in Serine-to-Glycine amino acid sub-
stitution at the position 377 (Table 1, Figure 1). 
These two variants are located at the carboxy-termi-
nal segment that plays an essential role in regulating the 
GATA4 transcription activity8. Indeed, Gallagher et al. 
proved that CDK4, a crucial protein required to activate 
theCyclinD2-GATA4 transcriptional synergy in cardio-
genesis interacts directly with GATA4 via its C-terminal 
region (362-440 aa) , which shows the potential role of  
GATA4 C-terminal through the heart development pro-
cess27. 
The non-synonymous variant S377G is located near to 
the nuclear localization signal (NLS), a domain respon-
sible of  transporting the GATA4 protein to the nucleus. 
In order to determine whether this mutation affects the 
NLS function, Wang et al. carried out immunofluores-
cence staining for GFP-tagged GATA4 in human car-
diomyocytes cells. The result shows that a small amount 
of  S377G GATA4 mutants, among other NLS adjacent 
mutants, was detected in the cytoplasmic region.  Such 
localisation pattern was considered a partially abnormal, 
compared to the wildtype pEGFP-GATA4 that was ex-
clusively localised in the nucleus. This finding suggests 
that S377G may partially impair the GATA4 protein traf-
ficking28.
However, since several studies reported that the variant 
Ser377Gly was frequently observed in both affected and 
healthy groups, often with no significant difference6,29,30, 
it could be considered as possibly benign.
On the other hand, the non-synonymous variant Val-
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380Met was proven to have no impact in the protein sec-
ondary structure and was detected among healthy groups 
in several studies. Moreover, the codon Val380 seems to 
be weakly conserved through species4,31-33. These data 
lead us to conclude that this variant is likely benign. 
Mutation screening allowed us to identify five additional 
variants (c.627C>T, c.687G>A, c.699G>A, c.1056C>T, 
c.1113A>G), one of  them constitutes a non-previous-
ly-reported variant, c.687G>A. These variants were 
identified in one patient each, and found to be synon-
ymous mutations (Asp209Asp, Arg229Arg, Thr233Thr, 
Asn352Asn, Ser371Ser) (table 1, Figure 1). 
As these silent mutations have obviously no damaging ef-
fect on protein conformation, we checked their possible 
earlier effect on splicing function during the post-tran-
scriptional process34-36. We tested hence whether or not 
those variants are located in a critical exonic splicing en-
hancer (ESE) or silencer (ESS) sites using Human Splic-
ing Finder tool (HSF 3.0)37. 
Interestingly we found that except the variant c.1113A>G 
(Ser371Ser) that has no particular impact, the remaining 
four variants have an interesting effect on splicing func-
tion. Indeed, the novel synonymous variant c.687G>A 
(Arg229Arg) leads to a potential alteration of  splicing 
function by altering an exonic splicing enhancer (ESE) 
site. The synonymous variant c.1056C>T (Asn352Asn) 
results in a creation of  anexonic splicing silencer (ESS) 
site, while the synonymous variants c.627C>T (As-
p209Asp) and c.699G>A (Thr233Thr) lead to a creation 
of  an ESS site, simultaneously with an alteration of  an 
ESE site, which constitutes a potential source of  splicing 
impairment.  Disruption of  splicing function with such 
variants can result in skipping the involved exons and 
thus forming alternative isoforms that may be non-func-
tional, or at least contribute in destabilising the GATA4 
isoforms balance7. 
Given that GATA4 is a highly dosage-sensitive protein, a 
slight change in the level of  protein expression by such 
isoform balance disruption, may lead to potential cardi-
ac morphogenesis impairment, involving life-threatening 
embryonic complications38.  
This significant impact is related to the pivotal role that 
GATA4 plays in proliferation of  cardiomyocytes, devel-
opment of  right ventricle and endocardial cushion, and in 
septation of  the outflow tract39,40. 
Tomita et al. noticed in TOF subgroup a significantly 
higher rate of  silent variants compared to the non-synon-
ymous variants (p = 0.03), and thus suggested that silent 
variants may be a potential genetic cause involved specif-
ically in TOF subset7. In our cohort, we noticed a high 
number of  synonymous mutations, but the difference 
was not significant. 
In addition to these exonic variants, we identified several 
non-coding polymorphisms that were clustered mainly in 
introns 1 and 4 (Table 2). We used the Human Splicing 
Finder (HSF 3.0)37 to check the impact of  these non-cod-
ing variants on splicing machinery, but we did not found a 
particular altering effect. 
It is worth to mention that 71% of  the studied pa-
tients carry at least one variant that is, in 90% of  cases, 
non-coding polymorphism. This data matches the con-
clusion made by Tomita and al. who noticed that amongst 
all CHD patients, those with conotruncal carry a substan-
tial number of  non-coding variants, unlike control groups 
that did not harbour such amounts. This may suggest a 
possible CHD-predisposing effect, though the molecular 
mechanism has yet to be elucidated7.
Taken together, this data shows the absence of  patho-
genic or likely pathogenic mutations of  GATA4 gene in 
the studied Moroccan population. This prompts further 
molecular investigations in the other genetic factors of  
cardiogenesis pathways, particularly, those involved in the 
second heart field differentiation and the heart looping 
process (e.g. NKX2.5, TBX1 …). 
Conclusion
The present study emphasises particularly the association 
of  GATA4 silent mutations with conotruncal defects, 
and supports the critical role of  GATA4 with its high-
ly sensitive dosage in the developmental process of  the 
outflow-tract. On the other hand, this study confirms 
the strong involvement of  maternal passive smoking in 
increasing the risk of  TOF, and underlines notably the 
heterogeneity of  the cardiac defects aetiology. Finally, 
to have a full overview about the aetiology of  TOF in 
Morocco, it would be pertinent to conduct a case-control 
study in a larger cohort; to screen GATA4 gene in a con-
trol group as well, in order to compare variant frequency 
between healthy and affected cohorts; and also to con-
sider more additional genetic and environmental factors.
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